Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/7/2026

1. ZS
2. LULU
3. IOT
4. SPY
5. PATH
6. DOCU
7. ASAN
8. NVDA
9. CIEN
10. GWRE

Go back to Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers
(NASDAQ: PPCB) Delayed: 1.01 -0.01 (0.98%)
Previous Close $1.02    52 Week High $ 
Open $1.05    52 Week Low $ 
Day High $1.05    P/E N/A 
Day Low $0.97    EPS $ 
Volume 194,403       

(NASDAQ: PPCB) Delayed: 1.01 -0.01 (0.98%)
Previous Close $1.02    52 Week High $ 
Open $1.05    52 Week Low $ 
Day High $1.05    P/E N/A 
Day Low $0.97    EPS $ 
Volume 194,403